摘要
血脂异常是心血管疾病的重要危险因素,PCSK9类抑制剂为一类新的降脂药物,可有效降低低密度脂蛋白胆固醇并预防心血管事件的发生。本研究旨在从促进合理用药角度出发,基于多准则决策分析方法,从安全性、有效性、经济性、适宜性、可及性五个维度对依洛尤单抗和阿利西尤单抗进行评价。根据相关指南建立临床综合评价指标体系,使用德尔菲法对指标体系进行修改和赋权。通过文献综述、网状meta分析和专家咨询搜集整合两药品在各维度的信息和证据,通过客观绩效得分标化法处理两药品在指标下得分并纳入指标体系进行计算。结果显示依洛尤单抗各维度得分均高于阿利西尤单抗,该结果在敏感性分析中保持一致。建议可优先使用依洛尤单抗以提升合理用药水平。
Dyslipidemia is an important risk factor of cardiovascular diseases.PCSK9 inhibitors are a new class of lipid-lowering drug,which can effectively reduce the density lipoprotein cholesterol and prevent the occurrence of cardiovascular events.To promote rational drug use,this study aimed to evaluate evolocumab and alirocumab from five dimensions(safety,effectiveness,economy,suitability and accessibility)based on multi-criteria decision analysis.The clinical comprehensive evaluation index system was established according to related guidelines,and the Delphi method was used to modify and empower the index system.Information and evidence of the two drugs in various dimensions were collected and integrated through literature review,network meta-analysis and expert consultation.The scores of the two drugs under the indicators were processed by the objective performance scoring method and included in the index system for calculation.The scores of all dimensions of evolocumab were higher than those of alirocumab,which remained consistent in the sensitivity analysis,suggesting preference of evolocumab.
作者
刘宇晗
胡嘉浩
朱碧帆
潘星明
金春林
李芬
LIU Yu-han;HU Jia-hao;ZHU Bi-fan;PAN Xing-ming;JIN Chun-lin;LI Fen(Shanghai Health Development Research Center(Shanghai Medical Information Center),Shanghai 200040)
出处
《中南药学》
2023年第8期2125-2132,共8页
Central South Pharmacy
